Long-term prognostic implications of the ADHF/NT-proBNP risk score in patients admitted with advanced heart failure

E.A.B. received consulting fees from Baldacci and Servier and travel/hotel/registration fee subsidies from Baldacci, Servier, Berlin Heart GmbH and Novartis. He is also a member of the steering committees of Servier, Novartis, Astra-Zeneca and Merck/Bayer; has performed “contracted research” from Servier and Amgen; and has received honoraria from Servier. The remaining authors have no conflicts of interest to disclose. This trial was supported by a grant from the Sao Paulo Research Foundation (2012/06163 to E. A.B.), Sao Paulo, Brazil (www.fapesp.br). No financial support was provided by any pharmaceutical company for the implementa tion, dissemination or publication of this study.